Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 351 - 400 of 1864 results
- Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
- Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy.
- Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.
- PEGylated J591 mAb loaded in PLGA-PEG-PLGA tri-block copolymer for targeted delivery: in vitro evaluation in human prostate cancer cells.
- Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy.
- Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth.
- Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.
- Antitumor therapeutic effects of e7 subunit and DNA vaccines in an animal cervical cancer model: antitumor efficacy of e7 therapeutic vaccines is dependent on tumor sizes, vaccine doses, and vaccine delivery routes.
- Production and upregulation of granulocyte chemotactic protein-2/CXCL6 by IL-1beta and hypoxia in small cell lung cancer.
- In vitro and in vivo evaluation of 111In-labeled E. coli heat-stable enterotoxin analogs for specific targeting of human breast cancers.
- Tumor cyclooxygenase-2 gene suppresses local immune responses in patients with hepatocellular carcinoma.
- Oncolytic measles virus targets high CD46 expression on multiple myeloma cells.
- A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy.
- Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.
- Natural killer T cell-mediated antitumor immune responses and their clinical applications.
- New target therapies in advanced pancreatic cancer.
- Antibody arrays: technical considerations and clinical applications in cancer.
- Tumor cells with B7.1 and transmembrane anchored staphylococcal enterotoxin A generate effective antitumor immunity.
- Prolongation of the survival of breast cancer-bearing mice immunized with GM-CSF-secreting syngeneic/allogeneic fibroblasts transfected with a cDNA expression library from breast cancer cells.
- TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models.
- Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo.
- Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer.
- A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients.
- Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.
- Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines.
- A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma.
- Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma.
- High-throughput, library-based selection of a murine leukemia virus variant to infect nondividing cells.
- Acacetin suppressed LPS-induced up-expression of iNOS and COX-2 in murine macrophages and TPA-induced tumor promotion in mice.
- Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells.
- Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
- IFN-gamma and T-bet expression in human dendritic cells from normal donors and cancer patients is controlled through mechanisms involving ERK-1/2-dependent and IL-12-independent pathways.
- Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene.
- Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death.
- Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.
- Structure-activity relationship studies on the immune stimulatory effects of base-modified CpG toll-like receptor 9 agonists.
- Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
- E1B55K-deleted adenovirus (ONYX-015) overrides G1/S and G2/M checkpoints and causes mitotic catastrophe and endoreduplication in p53-proficient normal cells.
- Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective.
- Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
- ReGel polymer-based delivery of interleukin-2 as a cancer treatment.
- Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
- Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.
- BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway.
- Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
- Particle-mediated cytokine gene therapy leads to antitumor and antimetastatic effects in mouse carcinoma models.
- Synthesis and evaluation of some lipidic aminoalcohols and diamines as immunomodulators.
- Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
- Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy.